.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its leading biopharma pick for 2025 as well as measured another 9 titles in the space as over weight. The assets bank claimed in a details that it remains to think “diabesity is actually set to come to be.